Overview

Immuno Oncology Assays Market to value over US $ 6 billion and register a CAGR of over 12% during the forecast period from 2020 to 2027.

Increase in the incidence of cancer, advancements in technology particularly in molecular techniques, extensive research undertaken and development in cancer diagnostics, and ongoing clinical trials in cancer immunotherapy is expected to accelerate the immuno oncology assays market. According to the World Health Organization (WHO), cancer accounted for 8.8 million deaths worldwide. One out of six deaths is due to cancer. Hence, an increase in the prevalence of cancer and the rising need for personalized medicine is expected to drive the immune oncology assays market during the forecast period. With the introduction of highly sensitive molecular techniques such as next-generation sequencing (NGS) and digital PCR (dPCR), researchers and clinicians can analyze various circulating biomarkers. These innovative technologies provide an economical and minimally invasive way for diagnosis, prognosis, and therapy selection in patients throughout their treatment plan thus bolstering the market worldwide.

Based on technology, the Immuno-Oncology Assays Market is segmented into PCR, immunoassay, NGS, flow cytometry, and other technologies. The NGS segment is estimated to be the segment growing with the highest CAGR during the forecast period. The integration of economical costs and advanced NGS technologies, rising government funding for sequencing projects, growing adoption of high-throughput sequencing technologies in emerging economies, and new product launches in immuno-oncology biomarker discovery are some of the key factors propelling the growth of the NGS segment.

On the basis of application, the Immuno-Oncology Assays Market is segmented into research applications and clinical diagnostics. Research applications dominated the market by holding the major market share. It is also forecasted to be the fastest-growing segment during the forecast period. The rising prominence of biomarker-based drug development and clinical trials and the emergence of cancer immunotherapy are the key factors driving market growth.

Based on region, North America and Europe are expected to be major markets for the immuno oncology assays market. Sound health care infrastructure and funding from public and private sectors for research and development are projected to fuel the market in these regions. According to the American Cancer Society, an estimated 1,735,350 new cancer cases will be diagnosed and 609,640 cancer deaths will occur in the U.S. Asia Pacific is expected to account for a significant share of the market during the forecast period. Federal support and innovation of novel therapeutics in the field of cancer is anticipated to drive the market in the region.

Prominent Players operating in the global immuno-oncology assays industry are:

Thermo Fisher Scientific (US), Roche Diagnostics (Switzerland), Agilent Technologies (US), and Illumina (US).

Market Segmentation

By Product

● Consumables

● Software

By Technology

● PCR

● Immunoassay

● Ngs

● Flow Cytometry

● Other Technologies

By Indication

● Lung Cancer

● Colorectal Cancer

● Melanoma

● Bladder Cancer

● Other Cancers

By Application

● Research Applications

● Clinical Diagnostics

By Region

● Europe

● North America

● APAC

● Latin America

● Rest of World

Competitive Landscape:

● Tier 1 players- established companies in the market with a major market share

● Tier 2 players

● Emerging players which are growing rapidly

● New Entrants 

FutureWise Takeaways

● Growth prospects

● SWOT analysis

● Key trends

● Key data points affecting market growth

Objectives of the Study:

● To provide an exhaustive analysis on the global immuno oncology assays market by product, by technology, by indication by application, and by region

● To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)

● To evaluate and forecast micro-markets and the overall market

● To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the rest of the world

● To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions

● Profiling of companies to evaluate their market shares, strategies, financials and core competencies

Table of Contents

1 Introduction 

    1.1 Objectives of the Study 

    1.2 Market Definition 

    1.3 Market Scope 

           1.3.1 Markets Covered

           1.3.2 Years Covered for the Study

    1.4 Currency 

    1.5 Limitations 

    1.6 Stakeholders 

2 Research Methodology 

    2.1 Primary Data 

           2.1.1 Key Data From Primary Sources

           2.1.2 Key Industry Insights

    2.2 Secondary Data 

           2.2.1 Key Data From Secondary Sources

    2.3 Market Size Estimation 

    2.4 Market Breakdown and Data Triangulation 

           2.4.1 Assumptions for the Study

3 Executive Summary 

       3.1 Market Outlook

      3.2 Segment Outlook

      3.3 Competitive Insights

4 Immuno-Oncology Assays Market, Premium Insights 

    4.1 Immuno-Oncology Assays: Market Overview 

    4.2 North America: Market, By Product and Country (2019) 

    4.3 Market, By Application (2019 vs 2027) 

    4.4 Market, By Technology (2019 vs 2027) 

    4.5 Geographical Snapshot of the Market 

5 Market Overview 

    5.1 Introduction 

    5.2 Market Dynamics 

           5.2.1 Drivers

                    5.2.1.1 Rising Incidence of Cancer and Increasing Adoption of Targeted Therapy

           5.2.2 Restraints

                    5.2.2.1 Unfavorable Regulatory and Reimbursement Scenario

                    5.2.2.2 High Amount of Capital Investments and Low Benefit-Cost Ratio

           5.2.3 Opportunities

                    5.2.3.1 Companion Diagnostics

6 Immuno-Oncology Assays Market, By Product

    6.1 Introduction 

    6.2 Consumables 

           6.2.1 Consumables Segment Will Continue to Dominate the Market During the Forecast Period

    6.3 Software 

           6.3.1 The Need to Deliver Accurate and Timely Analysis of Diagnostic Tests has Resulted in the Increased Adoption of Software

7 Immuno-Oncology Assays Market, By Technology 

    7.1 Introduction 

    7.2 PCR 

           7.2.1 Emergence of Advanced PCR Technologies to Support Market Growth

    7.3 Immunoassay 

           7.3.1 Immunoassays Have the Potential to Reduce Cancer Mortality Rate By Facilitating the Diagnosis of Cancer in the Early Stage

    7.4 Ngs 

           7.4.1 Ngs Segment to Register the Highest Growth Rate During the Forecast Period

    7.5 Flow Cytometry 

           7.5.1 Flow Cytometry Plays A Critical Role in Clinical Research Studies

    7.6 Other Technologies 

8 Immuno-Oncology Assays Market, By Indication 

    8.1 Introduction 

    8.2 Lung Cancer 

           8.2.1 Increasing R&D Activities on Lung Immuno-Oncology Assays is A Key Market Driver

    8.3 Colorectal Cancer 

           8.3.1 High Success Rate of Immuno-Oncology Assays in Crc Treatment Decisions to Drive Market Growth

    8.4 Melanoma 

           8.4.1 Growing Cases of Melanoma to Drive Market Growth

    8.5 Bladder Cancer 

           8.5.1 Bladder Cancer Segment to Witness Slower Growth Owing to the Limited Adoption of Immuno-Oncology Assays

    8.6 Other Cancers 

9 Immuno-Oncology Assays Market, By Application 

    9.1 Introduction 

    9.2 Research Applications 

           9.2.1 Rising Prominence of Biomarker-Based Drug Development and Clinical Trials to Drive the Research Applications Market

    9.3 Clinical Diagnostics 

           9.3.1 Benefits of Immuno-Oncology Assays are Driving Its Adoption in Clinical Diagnostics

10 Immuno-Oncology Assays Market, By Region (Page No. - 56)

     10.1 Introduction 

     10.2 North America 

             10.2.1 US

                        10.2.1.1 Increasing Demand for Immunotherapy Medicine Forms A Key Driver of Market Growth in the US

             10.2.2 Canada

                        10.2.2.1 High Burden of Cancer to Drive the Demand for Immuno-Oncology Assays

     10.3 Europe 

             10.3.1 Rising Focus on Biomarker Development in Several Eu Countries to Support Market Growth

     10.4 Asia Pacific 

             10.4.1 Increasing Demand for Better Healthcare Services in Developing Economies Will Contribute to Market Growth

     10.5 Rest of the World 

11 Competitive Landscape 

     11.1 Overview 

     11.2 Vendor Benchmarking 

     11.3 Competitive Leadership Mapping 

             11.3.1 Visionary Leaders

             11.3.2 Innovators

             11.3.3 Dynamic Differentiators

             11.3.4 Emerging Companies

     11.4 Market Ranking Analysis, 2017 

     11.5 Competitive Situation and Trends 

             11.5.1 Collaborations

             11.5.2 Product Launches

             11.5.3 Acquisitions

             11.5.4 Expansions

12 Company Profiles

(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, FutureWise View)*

     12.1 Thermo Fisher Scientific, Inc. 

     12.2 Roche Diagnostics 

     12.3 Agilent Technologies, Inc. 

     12.4 Illumina, Inc. 

     12.5 Nanostring Technologies, Inc. 

     12.6 Sartorius AG 

     12.7 Foundation Medicine 

     12.8 HTG Molecular Diagnostics, Inc. 

     12.9 Qiagen 

     12.10 Merck 

     12.11 Perkinelmer 

Tables

Figures